Navigation Links
Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
Date:12/10/2010

SAN ANTONIO Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

"We had a primary goal to compare the standard anti-HER2 neoadjuvant combination of chemotherapy, trastuzumab, with the new combination of chemotherapy and lapatinib," said Michael Untch, M.D., head of the multidisciplinary breast cancer department at Helios Clinic in Berlin, Germany.

The GeparQuinto study was conducted at 85 centers throughout Germany and includes 2,500 patients, 550 of whom have HER2-neu-overexpressing breast cancer. This is the largest prospective patient cohort of chemo-targeted neoadjuvant therapy worldwide.

All patients received four cycles of 90 mg/m2 epirubicin and 600 mg/m2 cyclophosphamide every three weeks, followed by four cycles of 100 mg/m2 docetaxel. They were randomly assigned to also receive concomitant 6 mg/kg trastuzumab every three weeks or 1,250 mg lapatinib per day throughout all cycles.

At baseline, patient characteristics were similar between the two groups, with both groups presenting a clinical median tumor size of 40 mm. The researchers also reported a similar number of patients in each group with T4a-c or T4d disease, bilateral, multifocal or multicentric disease, and estrogen receptor-negative and progesterone receptor-negative disease.

The last of the patients are currently undergoing surgery, and Untch will present histological and surgical outcome results for these patients at the symposium.

"After assessing response to neoadjuvant chemo-targeted therapy in patients with HER2 overexpressing tumors, we are following the patients from this study to see whether pathologic complete response at surgery is correlated to the outcome of the patients," he said.

<
'/>"/>
Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
2. PAREXEL Completes 200 Patient Studies In Its Early Phase Units Over Three Years
3. OHSU Doernbecher Childrens Hospital conducts second phase of landmark Batten study
4. Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS
5. First X-ray lasers early success brings approval for next-phase facility
6. ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human])
7. Registration Opens for Next Testing Phase of IEEE Certified Biometrics Professional Program
8. First phase of pan-tropical forest mapping debuting at COP15
9. NIH funds new phase of high school-university research partnership
10. Scientists seek new emphases in Arctic climate change research
11. Resolvyx announces positive data -- Phase 2 trial of resolvin RX-10045 for dry eye syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, ... ), the leading developer of human interface ... authentication technology, the industry,s first fully hardware ... innovative Match-in-Sensor secure authentication technology is literally ... pattern storage and biometric matching within the ...
(Date:7/8/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a ... launch of a study that aims to determine ... technology for predicting response to treatment in advanced ... the novel immunotherapy agents Yervoy® (ipilumumab), a CTLA-4 ... 50-patient study will be led by researchers at ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... poisonous frog was recently discovered in a remote mountainous ... supported by the Conservation Leadership Programme (CLP). The new ... given the name the ?golden frog of Supat. ... to several other common species in the area. However, ...
... of highly organized epithelial cells line all the cavities ... the movement of liquids,and cells in the body organs. ... serve as a barrier against cancer, according to a,study ... week in,the online edition of the Proceedings of the ...
... today by the Health Department shed new light on the ... who responded to the World Trade Center disaster on September ... Health Registry, show that 3.6% of the 25,000 rescue and ... working at the site. That rate is 12 times what ...
Cached Biology News:Cells united against cancer 2Survey finds elevated rates of new asthma among WTC rescue and recovery workers 2Survey finds elevated rates of new asthma among WTC rescue and recovery workers 3
(Date:8/3/2015)... ... August 03, 2015 , ... Sterlitech Corporation introduces ... comprehensive line of analytical laboratory equipment. With optimized features, such as PTFE-coated contact ... chemically resistant and maintenance-free solution for a broad range of vacuum filtration applications. ...
(Date:7/31/2015)... , July 31, 2015 In ... resources that help them drive positive health outcomes, ... vital source of patient care in their communities. ... annual tradeshow and conference, AmerisourceBergen announced a new ... Pharmacy Services Administration Organization and help independent pharmacies ...
(Date:7/31/2015)... ... 31, 2015 , ... Global Resorcinol Market 2015-2019 is a ... the global resorcinol industry. The report highlights the various growth prospects and the ... analysis of primary and secondary inputs from the existing players of the resorcinol ...
(Date:7/31/2015)... July 31, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory ... services, today announced that the Company has filed its ... and Exchange Commission. The filed Form 20-F includes audited ... 2015. The Form 20-F can be accessed by visiting ...
Breaking Biology Technology:Sterlitech Launches New Line of Vacuum Pumps 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2
... Research conducted at The,Walter and Eliza Hall ... licensing agreement signed between Australian biotechnology company,Bionomics, ... Under the Development and Licensing Agreement, Merck ... multiple sclerosis (MS) and other autoimmune,conditions. These ...
... -- WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology ... operations in China and the United,States, today announced ... Vice President,of Human Resources., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ... Mr. Zhu worked as Head of Asia Human,Resources ...
... Antonio (June 30, 2008) Researchers at The University of ... Infectious Diseases and The University of Texas Health Science Center ... to play a role in controlling the early infectious process ... agent that is the cause of tularemia. The findings will ...
Cached Biology Technology:MS Drug Development Agreement Based on WEHI's Medicinal Chemistry 2WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR 2UTSA/UTHSCSA publish results on bio-threat agent 2